nach oben

Drugs & Aging

Erschienen in:

01.08.2000 | Review Article

Potential Applications of Gene Therapy in the Patient with Cancer

verfasst von: Dr Piotr W. Szlosarek, Angus G. Dalgleish

Erschienen in: Drugs & Aging | Ausgabe 2/2000

Einloggen, um Zugang zu erhalten

Abstract

The elderly population has much to gain from the advances of molecular medicine, although at present genetic pharmacology remains mostly at the conceptual level. Cancer, in particular, is an increasing health burden and the majority (over 70%) of gene therapy trials are aimed at tackling this problem. Available strategies employ both viral and synthetic vectors with the selective delivery and expression of therapeutic genes a pivotal requirement. Clinical trials are now in progress with a view to modulating disease at many different levels, including the direct replacement of abnormal genes, suicide-gene formulations, and the delivery of ‘gain of function’ genes, which seek to alter the malignant phenotype by indirect means, such as, immunopotentiation and stromal reorganisation. Early data from these studies is tantalising and we must remain optimistic that gene therapy will benefit the patient with cancer by both reducing morbidity and extending life.

Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570–8PubMed

Blaese RM, Culver KW, Miller AD, et al. T-lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 475–80PubMed

Eliasson MJL, Sampei K, Mandir AS, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischaemia. Nat Med 1997; 3: 1089–95PubMed

Stenbit AE, Tsu-Shuen T, Li J, et al. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 1997; 3: 1096–101PubMed

Carroll JL, Bell MC, Gameau LJ, et al. Analysis of a bystander effect in vivo following adenovirus-based p53 gene therapy [abstract]. Proc Am Assoc Cancer Res 1999; 40: 3280

Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 1993; 90: 7024–8PubMed

Wei MX, Tamiya T, Rhee RJ, et al. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1995; 1: 1171–7PubMed

Elshami AA, Saavendra A, Zhang H, et al. Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. GeneTher 1996; 3: 85–92

Vile RG, Castledon S, Marshall J, et al. Generation of an anti-tumour response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int J Cancer 1997; 71: 267–74PubMed

10.

Nishizaki M, Fujiwara T, Tanida T, et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 1999; 5: 1015–23PubMed

11.

Patel PI. Identification of disease genes and somatic gene therapy: an overview and prospects for the aged. J Gerontology 1993; 48: B80–5

12.

Blaese M, Blankenstein T, Brenner M, et al. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther 1995; 2: 291–7PubMed

13.

Nabel GJ. Development of optimized vectors for gene therapy. Proc Natl Acad Sci U S A 1999; 96: 324–6PubMed

14.

Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21–39PubMed

15.

Dranoff G. Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol 1998; 16: 2548–56PubMed

16.

Anderson WF. Human gene therapy. Nature 1998; 392 Suppl.: 25–30PubMed

17.

Patterson A, Harris AL. Molecular chemotherapy for breast cancer. Drugs Aging 1999; 14: 75–90PubMed

18.

Clayman GL, El-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221–32PubMed

19.

Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nat Med 1998; 4: 1341–2PubMed

20.

Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287–91PubMed

21.

Pirollo KF, Hao Z, Rait A, et al. p53-mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997; 14: 1735–46PubMed

22.

Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 1125–35PubMed

23.

Wang Q, Finer MH. Second-generation adenovirus vectors. Nat Med 1996; 2: 714–6PubMed

24.

Nevins JR. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 1981; 26: 213–20PubMed

25.

Halbert DN, Cutt JR, Shenk T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985; 56: 250–7PubMed

26.

Gorziglia MI, Lapacevich C, Roy S, et al. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J Virol 1999; 73: 6048–55PubMed

27.

Muruve DA, Barnes MJ, Stillman IE, et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965–76PubMed

28.

Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nature Med 1999; 5: 1256–63PubMed

29.

Gene therapy: a loss of innocence [editorial]. Nat Med 2000; 6: 1

30.

Kim CJ, Cormier J, Roden M, et al. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann Surg Oncol 1998; 5: 64–76PubMed

31.

Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates in p53-deficient human tumor cells. Science 1996; 274: 373–6PubMed

32.

Hall AR, Dix BR, O’Carroll SJ, et al. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4: 1068–72PubMed

33.

Kirn D, Nemunaitis J, Ganly I, et al. A phase II trial with an EIB-deleted adenovirus, ONYX-015, in patients with recurrent refractory head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17: 1509

34.

Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639–45PubMed

35.

Freytag SO, Rogulski KR, Paielli DL, et al. A novel three-pronged approachto kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323–33PubMed

36.

Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of relication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 200; 7: 859–66

37.

Markert JM, Medlock MD, Rabkin SD. Conditinally relicating herpes simples virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 200; 7: 867–74

38.

Nalbantoglu J, Pari G, Karpati G, et al. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther 1999; 10: 1009–19PubMed

39.

Li Y, Rey-Chen P, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325–30PubMed

40.

Gropp R, Michaela F, Wagner TOF, et al. Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy. Hum Gene Ther 1999; 10: 957–64PubMed

41.

Bosse R, Singhofer-Wowra M, Rosenthal F, et al. Good manufacturing practice production of human stem cells for somatic cell and gene therapy. Stem Cells 1997; 15 Suppl. 1: 275–80

42.

Linden RM, Woo SLC. Avant-garde gene therapy. Nat Med 1999; 5: 21–2PubMed

43.

Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–4PubMed

44.

Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873–80PubMed

45.

Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354–7PubMed

46.

Langer R. Drug delivery and targeting. Nature 1998; 392 Suppl.: 5–10PubMed

47.

Tang WH, Xu L, Pirollo KF, et al. A ligand-directed, tumor-targeting systemic gene delivery system [abstract]. Proc Am Assoc Cancer Res 1999; 40: 4167

48.

Murray JL, Yoo GH, Lopez-Berestein G, et al. Phase I trial of intratumoral liposomal-E1A gene therapy in patients with recurrent/refractory breast cancer (BC) and head and neck (H&N) cancer [abstract]. Proc Am Soc Clin Oncol 1998: 17; 1662

49.

Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996; 93: 15388–93PubMed

50.

Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985–91PubMed

51.

Hang Y, Mukhopadhyay T, Donehower LA, et al. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993; 4: 451–60

52.

Monia BP, Johnston JF, Geiger T, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996; 2: 668–74PubMed

53.

Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137–41PubMed

54.

Ho PT, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997; 24: 187–202PubMed

55.

Akhtar S, Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 1997; 18: 12–8PubMed

56.

Tortora G, Caputo R, Pomatico G, et al. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination woth docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin Cancer Res 1999; 5: 875–81PubMed

57.

Yamamoto T, Yamamoto S, Kataoka T, et al. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev 1994; 4: 119–22PubMed

58.

Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nat Med 1997; 3: 849–54PubMed

59.

Chong H, Vile R. Gene therapy for cancer. Drugs Future 1997; 22: 857–74

60.

Perry MA, Todryk S, Dalgleish AG. The role of HSVtk in the treatment of solid tumours. Expert Opin Invest Drugs 1999; 8: 777–85

61.

Hamel W, Magnelli L, Chirarugi V, et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996; 56: 2697–302PubMed

62.

Craperi D, Vicat JM, Nissou MF, et al. Increased Bax expression is associated with cell death induced by ganciclovir in a herpes thymidine kinase gene-expressing glioma cell line. Hum Gene Ther 1999; 10: 679–88PubMed

63.

Barba D, Hardin J, Sadelain M, et al. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 1994; 91: 4348–52PubMed

64.

Izquierdo ML. An overview of gene therapy approaches to neurological malignancies. BioDrugs 1998; 9: 337–49PubMed

65.

Ram Z, Culver KW, Oshiro ME, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producer cells. Nat Med 1997; 3: 1354–61PubMed

66.

Klatzmann D, Cherin P, Bensimon G, et al. Aphase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase ‘suicide’ gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 1998; 9: 2585–94PubMed

67.

Ido A, Nakata K, Kato Y, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995; 55: 3105–9PubMed

68.

Chen L, Chen D, Manome Y, et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995; 96: 2775–82PubMed

69.

Vandier D, Rixe O, Brenner M, et al. Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes sinplex virus-thymidine kinase gene. Cancer Res 1998; 58: 4577–80PubMed

70.

Mullen C, Kilstrup M, Blaese R. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A 1992; 89: 33–7PubMed

71.

Mullen CA, Coale MM, Lowe R, et al. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res 1994; 54: 1503–6PubMed

72.

Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994; 91: 8302–6PubMed

73.

Cao G, Kuriyama S, Gao J, et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther 1999; 6: 83–90PubMed

74.

Bordignon C, Bonini C, Verzeletti S, et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 1995; 6: 813–9PubMed

75.

Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719–24PubMed

76.

Verzeletti S, Bonini C, Marktel S, et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 1998; 9: 2243–51PubMed

77.

Dalgleish AG, Browning MJ, editors. Tumour immunology: immunotherapy and cancer vaccines. Cambridge: Cambridge University Press, 1996

78.

Human gene marker/therapy clinical protocols. Hum Gene Ther 1999; 10: 1043–92

79.

Asher AL, Mule JJ, Kasid A, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha: evidence for paracrine immune effects of tumour necrosis factor-alpha against tumors. J Immunol 1991; 146: 3227–34PubMed

80.

Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403PubMed

81.

Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217–24PubMed

82.

Hock H, Dorsch M, Diamantstein, et al. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1991; 174: 1291–8PubMed

83.

Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90: 3539–43PubMed

84.

Lim M, Simons JW. Emerging concepts in GM-CSF gene-transduced tumor vaccines for human prostate cancer. Curr Opin Mol Ther 1999; 1: 64–71PubMed

85.

Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996; 2: 1090–5PubMed

86.

Paillard F. Cytokine and chemokine: a stimulating couple. Hum Gene Ther 1999; 10: 695–6PubMed

87.

Wallich R, Bulbuc N, Hammerling GH, et al. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985; 315: 301–5PubMed

88.

Plaskin D, Gelber C, Feldman M, et al. Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2K^b gene. Proc Natl Acad Sci U S A 1988; 85: 4463–7

89.

Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368–70PubMed

90.

Putzer BM, Hitt M, Mueller Wl, et al. Interleukin-12 and B7-I costimulatory molecule expressed by an adenoviral vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci U S A 1997; 94: 10889–94PubMed

91.

Dalgleish AG. The case for therapeutic vaccines. Melanoma Res 1996; 6: 5–10PubMed

92.

Dalgleish AG. The development of therapeutic vaccines of the management of malignant melanoma. Cancer Surv 1996; 26: 289–319PubMed

93.

Hrouda D, Dalgleish AG. Gene therapy for prostate cancer. Gene Ther 1996; 3: 845–52PubMed

94.

Todryk SM, Chong H, Vile RG, et al. Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut 1998; 43: 445–9PubMed

95.

Abdel-Wahab Z, Weltz C, Hester D, et al. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells. Cancer 1997; 80: 401–12PubMed

96.

Schreiber S, Kämpgen E, Wagner E, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase 1 study. Hum Gene Ther 1999; 10: 983–93PubMed

97.

Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998; 95: 13141–6PubMed

98.

Hennemann B, Andreesen R. Monocyte/macrophage activation by immunostimulators. Clin Immunother 1996; 5: 294–308

99.

Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–51PubMed

100.

Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46: 82–7PubMed

101.

Zhong L, Granelli-Piperno A, Choi Y, et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999; 29: 964–72PubMed

102.

Diebold S, Lehrmann H, Kursa M, et al. Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum Gene Ther 1999; 10: 775–86PubMed

103.

Condon C, Watkins SC, Celluzzi CM, et al. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2: 1122–8PubMed

104.

Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat Med 1998; 4: 328–32PubMed

105.

Okada H, Tahara H, Shurin MR, et al. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 1998; 78: 196–201PubMed

106.

Reeves M, Royal R, Lam J, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996; 56: 5672–7PubMed

107.

Pérez-Díez A, Butterfield LH, Li L, et al. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res 1998; 58: 5305–9PubMed

108.

Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983; 157: 1040–52PubMed

109.

Topalian SL, Kasid A, Rosenberg SA. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. J Immunol 1990; 144: 4487–95PubMed

110.

Jäger E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Can 1997; 71: 142–7

111.

Miller PW, Sharma, S, Stolina M, et al. Intratumoral administration of cytokine gene-modified dendritic cells augments antigen presentation and processing in non-small cell lung cancer [abstract]. Proc Am Assoc Cancer Res 1999; 40: 572

112.

Cao X, Zhang W, He L, et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 1998; 161: 6238–44PubMed

113.

Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes. Cancer Res 1995; 55: 3369–73PubMed

114.

Wang G, Chopra RK, Royal RE, et al. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain gene recognising a human ovarian cancer antigen. Nature Med 1998; 4: 168–72PubMed

115.

Altenschmidt U, Moritz D, Croner B. Specific cytotoxic T lymphocytes in gene therapy. J Mol Med 1997; 75: 259–66PubMed

116.

Paillard F. Immunotherapy with T cells bearing chimeric antitumor receptors. Hum Gene Ther 1999; 10: 151–3PubMed

117.

Shiraki K, Tsuji N, Shioda T, et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A 1996; 94: 6420–5

118.

McGuiness RP, Ge Y, Patel SD, et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 1999; 10: 165–73

119.

Tahara H, Zeh Hl, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182–9PubMed

120.

Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996; 2: 1038–41PubMed

121.

Horton HM, Anderson D, Hernandez P, et al. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α. Proc Natl Acad Sci U S A 1999; 96: 1553–8PubMed

122.

Kong HL, Crystal RG. Gene therapy strategies for tumor anti-angiogenesis. J Natl Cancer Inst 1998; 90: 273–86PubMed

123.

Tanaka T, Manome Y, Wen P, et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angio-genesis and tumor growth. Nat Med 1997; 3: 437–42PubMed

124.

Valente P, Fassina G, Melchiori A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998; 75: 246–53PubMed

125.

Baker AH, George SJ, Zaltsman AB, et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 1999; 79: 1347–55PubMed

126.

Rigg AS, Waxman J, Lemoine NR. Gene therapy with TIMP1 or TIMP2 prolongs the survival and reduces the burden of disease for mice harboring intraperitoneal human pancreatic carcinomas [abstract]. Proc Am Assoc Cancer Res 1999; 40: 4169

127.

Oku T, Tjuvajec JG, Miyagawa T, et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 1998; 58: 4185–92PubMed

128.

Im SA, Gomez-Manzano C, Fueyo J, et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999; 59: 895–900PubMed

129.

Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor recptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998; 95: 8795–800PubMed

130.

Machein MR, Risau W, Plate KH. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 1999; 10: 1117–28PubMed

131.

Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963–70PubMed

132.

Cao Y, O’Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998; 101: 1055–63PubMed

133.

Tanaka T, Cao Y, Folkman J, et al. Viral vector-targeted anti-angiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998; 58: 3362–9PubMed

134.

Chen QR, Kumar D, Stass SA, et al. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999; 59: 3308–12PubMed

135.

Liu Y, Thor A, Shtivelman E, et al. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J Biol Chem 1999; 274: 13338–44PubMed

136.

Gottesman M. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53: 747–54PubMed

137.

Podda S, Ward M, Himelstein A, et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci U S A 1992; 89: 9676–80PubMed

138.

Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103PubMed

139.

Rafferty JA, Hickson I, Chinnasamy N, et al. Chemoprotection of normal tissues by transfer of drug resistance genes. Cancer Metastasis Rev 1996; 15: 365–83PubMed

140.

Hesdorffer C, Ayello J, Ward M, et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998; 16: 165–72PubMed

141.

Merrouche Y, Negrier S, Bain C, et al. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 1995; 13: 410–8PubMed

142.

Brenner MK, Rill DR, Moen RC, et al. Gene marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–6PubMed

143.

Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukaemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood 1994; 83: 3068–76PubMed

Titel: Potential Applications of Gene Therapy in the Patient with Cancer
verfasst von: Dr Piotr W. Szlosarek
Angus G. Dalgleish
Publikationsdatum: 01.08.2000
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 2/2000
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200017020-00004

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2000

Il Imidazoline Agonists. General Clinical Pharmacology of Imidazoline Receptors

Pharmacotherapy or Surgery as Primary Treatment for Acromegaly?

Community-Acquired Pneumonia in the Elderly